Head to Head Survey: Immatics (NASDAQ:IMTX) and Calidi Biotherapeutics (NYSE:CLDI)

Calidi Biotherapeutics (NYSE:CLDI) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation.

Insider and Institutional Ownership

12.5% of Calidi Biotherapeutics shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 24.3% of Calidi Biotherapeutics shares are held by insiders. Comparatively, 3.3% of Immatics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Calidi Biotherapeutics and Immatics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Calidi Biotherapeutics	N/A	N/A	-344.45%
Immatics	-47.94%	-15.90%	-9.38%

Analyst Ratings

This is a summary of recent recommendations and price targets for Calidi Biotherapeutics and Immatics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calidi Biotherapeutics	0	0	3	0	3.00
Immatics	0	0	4	1	3.20

Calidi Biotherapeutics presently has a consensus target price of $16.67, suggesting a potential upside of 1,049.43%. Immatics has a consensus target price of $16.67, suggesting a potential upside of 134.74%. Given Calidi Biotherapeutics’ higher possible upside, equities research analysts plainly believe Calidi Biotherapeutics is more favorable than Immatics.

Earnings and Valuation

This table compares Calidi Biotherapeutics and Immatics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calidi Biotherapeutics	$50,000.00	379.26	-$29.22 million	N/A	N/A
Immatics	$115.50 million	7.34	-$104.98 million	($0.66)	-10.76

Calidi Biotherapeutics has higher earnings, but lower revenue than Immatics.

Volatility & Risk

Calidi Biotherapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Immatics has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500.

Summary

Calidi Biotherapeutics beats Immatics on 7 of the 13 factors compared between the two stocks.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.